ASND — Ascendis Pharma A/S Cashflow Statement
0.000.00%
Last trade - 00:00- $9.96bn
- $10.30bn
- €363.64m
Annual cashflow statement for Ascendis Pharma A/S, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -419 | -384 | -583 | -481 | -378 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 138 | -2.56 | 89.2 | 124 | 230 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.047 | -46.9 | -19.6 | -129 | -175 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -272 | -418 | -496 | -467 | -306 |
| Capital Expenditures | -21.6 | -24.2 | -14.5 | -2.44 | -1.43 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | -270 | -86.3 | 76.2 | 289 | 8.3 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -291 | -111 | 61.7 | 286 | 6.88 |
| Financing Cash Flow Items | -31.4 | — | — | -1.81 | -19.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 603 | 351 | 397 | 134 | 444 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -13.6 | -138 | -1.5 | -52.6 | 167 |